From PsychonautWiki
(Redirected from STP)
Jump to: navigation, search
Summary sheet: DOM
Molecular structure of DOM
Chemical Nomenclature
Common names DOM, STP (Serenity, Tranquility, and Peace)
Substitutive name 2,5-Dimethoxy-4-methylamphetamine
Systematic name 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane
Class Membership
Psychoactive class Psychedelic
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 0.5 - 1 mg
Light 1 - 3 mg
Common 3 - 5 mg
Strong 5 - 10 mg
Heavy 10 mg +
Total 12 - 16 hours
Onset 1 - 2 hours
Come up 2 - 3 hours
Peak 6 - 8 hours
Offset 3 - 5 hours
After effects 4 - 16 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

2,5-Dimethoxy-4-methylamphetamine (also known as DOM and STP or "Serenity, Tranquility and Peace") is a synthetic psychedelic substance of the substituted amphetamine class of chemicals. It is a member of the DOx family of compounds which are known for their high potency, long duration, and unique mixture of psychedelic and stimulating effects.[citation needed]

DOM was first synthesized and tested in 1963 by Alexander Shulgin who was investigating the effect of 4-position substitutions on psychedelic amphetamines.[1] It attained some popularity during the summer of 1967 as a psychedelic drug under the name "STP" ("Serenity, Tranquility, and Peace"),[2] but widespread human use was short-lived. Subsequently, in 1991, the synthesis and pharmacology of DOM was published in Shulgin's book PiHKAL ("Phenethylamines I Have Known And Loved")[3].

This particular substance is part of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which except mescaline he developed and synthesized himself. They are found within the first book of PiHKAL and are as follows: Mescaline, DOM, 2C-B, 2C-E, 2C-T-2 and 2C-T-7.

Over the years, DOM has gained a reputation for being a highly dose-sensitive psychedelic that is often sold on blotting paper and known for its strong visuals, body load and neutral, analytical headspace. Many reports also indicate that the effects of this chemical may be overly difficult to use for those who are not already experienced with psychedelics.

Today, DOM is rarely encountered in the street and is used either as a recreational drug or as an entheogen.

History and culture

DOM was first synthesized and tested in 1963 by Alexander Shulgin, who was investigating the effect of 4-position substitutions on psychedelic amphetamines.[1]

In mid-1967, tablets containing 20 mg (later 10 mg) of DOM were widely distributed in the Haight-Ashbury District of San Francisco under the name of "STP" (short for "Serenity, Tranquility, and Peace").[citation needed]

This short-lived appearance of DOM on the black market proved disastrous for several reasons. First, the tablets contained an excessively high dose of the chemical. This, combined with DOM’s slow onset of action (which encouraged some users, familiar with substances that have quicker onsets, such as LSD, to re-dose) and its remarkably long duration, caused many users to panic and sent some to the emergency room. Second, treatment of such overdoses was complicated by the fact that it was unknown at the time that the tablets called "STP" were, in fact, DOM.[citation needed]


DOM, or 4-methyl-2,5-dimethoxyamphetamine, is a molecule of the substituted amphetamine class. Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα. DOM contains methoxy functional groups (OCH3) attached to carbons R2 and R5 and a methyl group attached to carbon R4 of the phenyl ring.

DOM is the amphetamine analogue of the phenethylamine 2C-D.[4][5]


Further information: Serotonergic psychedelic

DOM is a selective 5-HT2A, 5-HT2B, and 5-HT2C receptor partial agonist. Its psychedelic effects are mediated by its agonistic properties at the 5-HT2A receptor. Due to its selectivity, DOM is often used in scientific research when studying the 5-HT2 receptor subfamily.

DOM is a chiral molecule, and R-(-)-DOM is the more active enantiomer, functioning as a potent agonist of the serotonin family of receptors (mainly of the 5-HT2 subtype).[6]

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include injury or death.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational DOM use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because DOM is a research chemical with very little history of human usage.

Anecdotal evidence from those within the community who have tried DOM suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

DOM is not habit-forming and the desire to use it can decrease with use. It is most often self-regulating.

Tolerance to the effects of DOM are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). DOM presents cross-tolerance with all psychedelics, meaning that after the consumption of DOM all psychedelics will have a reduced effect.

Dangerous interactions

Although many psychoactive substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.


  • Brazil - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344 as "STP".[8]
  • Belgium: DOM is a Schedule I drug.[citation needed]
  • Canada: DOM is a Schedule I drug.[citation needed]
  • Latvia: DOM is a Schedule I controlled substance.[9]
  • New Zealand: DOM is a Class A drug.[citation needed]
  • Switzerland: Possession, production and sale is illegal.[10]
  • United Kingdom: DOM is a Class A drug.[citation needed]
  • United States: DOM is a Schedule I drug.[citation needed]

See also

External links



  1. 1.0 1.1 Shulgin, Alexander (1991). PiHKAL: A Chemical Love Story. Berkeley, CA: Transform Press. pp. 53–56.
  2. "STP's faster, here's why". Berkeley Barb, June 16-22, 1967. 3-5 (Independent Voices) |
  6. Sanders-Bush, Burris, KD; Knoth, K, (September 1988). "Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis"
  7. Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
  9. Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) |